Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007611-194806000-00008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in chronic kidney disease patients with renal anemia: a retrospective study.
BMC Nephrol
November 2024
Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Background: Although erythropoiesis-stimulating agents (ESAs) have been the standard treatment for renal anemia, ESA hyporesponsiveness remains a concern. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of agents indicated for renal anemia. Several lines of evidence indicate that HIF-PHIs affect erythrocyte indices; nonetheless, their clinical significance remains unclear.
View Article and Find Full Text PDFLow-Dose Aspirin and Risk of Anaemia in Older Adults: Insights from a Danish Register-based Cohort Study.
Eur Heart J Qual Care Clin Outcomes
October 2024
Department of Drug Design and Pharmacology, University of Copenhagen, Denmark.
Article Synopsis
- The study aimed to evaluate the risk of developing anemia in older Danish individuals (aged 65 and above) who used low-dose aspirin (LDA) for cardiovascular prevention between 2008 and 2013.
- Using Danish health registers, researchers tracked over 313,000 participants and found that LDA users had a significantly higher incidence of both hematinic deficiency (9.6%) and anemia (5.9%) compared to non-users.
- The results suggest that approximately 6 to 10 out of every 100 older adults using LDA may develop anemia within the first five years of treatment, highlighting the risks associated with LDA usage in this demographic.
Case Report: High-Dose Ferric Carboxymaltose as an Antianaemic Agent to Avoid Haemotransfusions after Total Hip Replacement.
Medicina (Kaunas)
August 2024
Department of Anesthesiology and Intensive Care, National Scientific Center of Traumatology and Orthopaedics Named after Academician N.D. Batpenov, Astana 010000, Kazakhstan.
This article highlights a case of high-dose ferric carboxymaltose (Ferinject) for the treatment of perioperative iron deficiency anaemia in a 39-year-old patient with dysplastic coxarthrosis. The patient was admitted routinely for a total hip replacement of the left hip joint. She had been suffering from pain, lameness, and restriction of movement in her left hip joint for the past several years.
View Article and Find Full Text PDFThe medication usage pattern and prevalence of polypharmacy among patients with sickle cell disease: a population-based study in southern Iran.
Expert Rev Hematol
September 2024
MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Due to the numerous complications associated with sickle cell disease (SCD), patients often receive a variety of medications alongside their SCD treatment. However, a notable gap exists in the current literature regarding medication use patterns among them. This study aimed to investigate medication usage patterns in patients with SCD.
View Article and Find Full Text PDFAnemia in patients receiving anticancer treatments: focus on novel therapeutic approaches.
Front Oncol
April 2024
Department of Medicine, Section of Internal Medicine, University of Verona, Verona, Italy.
Anemia is common in cancer patients and impacts on quality of life and prognosis. It is typically multifactorial, often involving different pathophysiological mechanisms, making treatment a difficult task. In patients undergoing active anticancer treatments like chemotherapy, decreased red blood cell (RBC) production due to myelosuppression generally predominates, but absolute or functional iron deficiency frequently coexists.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!